# Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Study · id `cardio:ct-nct05537571` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05537571](<https://clinicaltrials.gov/study/NCT05537571>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05537571

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT05537571. Randomized; double masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2024-01-11 (actual). Results posted on 2025-07-01.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT05537571, source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)
- Started: 2022-12-13 (actual) (ClinicalTrials.gov record NCT05537571, source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)
- Primary completion: 2024-01-11 (actual) (ClinicalTrials.gov record NCT05537571, source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)
- Completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT05537571, source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)
- Results first posted: 2025-07-01 (ClinicalTrials.gov record NCT05537571, source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)
- Countries: Australia; Czechia; Denmark; Netherlands; Slovakia; South Africa; United Kingdom (ClinicalTrials.gov record NCT05537571, source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05537571-2025-07-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- Condition: Cardiovascular Diseases
- Condition: Atherosclerosis
- Condition: Lipoprotein(a)
- Intervention (Drug): SLN360
- Intervention (Drug): Placebo
- Lead sponsor: Silence Therapeutics plc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial (`cardio:pubmed-39556769`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a8376dc0260711e9e18c3aa3e2916e4c5e6b9831d7dc29687a0c637227c6108d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
